Harrow Inc. has reaffirmed its 2025 full-year revenue guidance of $270–$280 million, indicating another year of strong growth for the company. The guidance reflects continued positive demand trends across Harrow’s key revenue-driving products and meaningful progress within other areas of its portfolio. The company is also executing expansion plans, including doubling the sales force for VEVYE®, broadening the commercial footprint of IHEEZO® to office-based settings, and increasing the commercial presence of TRIESENCE® in surgical settings. These initiatives are driven by growing momentum and customer interest in Harrow’s products.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Harrow Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9646742) on February 02, 2026, and is solely responsible for the information contained therein.
Comments